Drugs / MG01CI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02059642 | Mar → Sep 2014 | attention deficit hyperactivity disorder, inattentive type | Alcobra Ltd. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-09-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Results Teva and Alcobra Announce Phase II Trial of Novel, Non-Stimulant MG01CI for ADHD Meets Primary Endpoint tevapharm.com ↗
Results showed MG01CI met the primary efficacy outcome, demonstrating a significant improvement on the Conners' Adult ADHD Rating Scale-Investigator Rated Total ADHD Symptoms Score (CAARS-INV) compared to placebo (p<0.03). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-09-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Alcobra Announce Phase II Trial of Novel, Non-Stimulant MG01CI for ADHD Meets Primary Endpoint tevapharm.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG01CI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02059642 ↗ |
| Known as | Metadoxine | “MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily” NCT02059642 ↗ |
| Route | Oral | “administered orally once daily” NCT02059642 ↗ |